House oversight hearing of FDA approval programs may be held in the spring.
This article was originally published in The Gray Sheet
HOUSE OVERSIGHT CHAIRMAN BARTON FAVORS "SYSTEMATIC" CHANGES AT FDA over third-party review as a means of improving the efficiency of the agency's device and drug premarket programs. Speaking at a Jan. 12 press conference in Washington, D.C., Rep. Joe Barton (R-Tex.) said he "would not be willing to privatize the FDA."
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.